A phenotypic invitro model for the main determinants of human whole heart function

Biomaterials

Volumn 60, Issue , 2015, Pages 20-30

  Stancescu, Maria ^a   Molnar, Peter ^b,c   McAleer, Christopher W ^a   McLamb, William ^a   Long, Christopher J ^a   Oleaga, Carlota ^a   Prot, Jean Matthieu ^a,c   Hickman, James J ^a  

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

^b UNIVERSITY OF WEST HUNGARY   (Hungary)

^c School of Operations Research and Industrial Engineering   (United States)

Author keywords

Cardiomyocyte; Conduction; Force generation; Functional assay; Human; Serum free

Indexed keywords

HEART; HEAT CONDUCTION; STEM CELLS;

CARDIOMYOCYTES; FORCE GENERATION; FUNCTIONAL ASSAYS; HUMAN; SERUM FREE;

FUNCTION EVALUATION;

NORADRENALIN; SOTALOL; TROPONIN T; VERAPAMIL;

ARTICLE; BIOLOGICAL MODEL; BIOMEDICAL MICROELECTROMECHANICAL SYSTEM; CONTROLLED STUDY; EMBRYONIC STEM CELL; HEART CONDUCTION; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART MUSCLE POTENTIAL; HEART MUSCLE RELAXATION; HEART OUTPUT; HUMAN; HUMAN CELL; IN VITRO STUDY; INOTROPISM; PRIORITY JOURNAL; QT INTERVAL; CARDIAC MUSCLE CELL; CELL CULTURE; CELL CULTURE TECHNIQUE; CYTOLOGY; DEVICES; DRUG EFFECTS; EQUIPMENT DESIGN; HEART; MICROELECTRODE; MICROELECTROMECHANICAL SYSTEM; PHYSIOLOGY; PRECLINICAL STUDY;

CELL CULTURE TECHNIQUES; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; EQUIPMENT DESIGN; HEART; HUMANS; MICRO-ELECTRICAL-MECHANICAL SYSTEMS; MICROELECTRODES; MYOCYTES, CARDIAC;

EID: 84930434509     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.035     Document Type: Article

References (50)

1. Carlsson L. Invitro and invivo models for testing arrhythmogenesis in drugs. JIntern Med 2006, 259:70-80.
2. Lawrence C.L., Pollard C.E., Hammond T.G., Valentin J.P. Nonclinical proarrhythmia models: predicting torsades de pointes. JPharmacol Toxicol Methods 2005, 52:46-59.
3. Suter W. Predictive value of invitro safety studies. Curr Opin Chem Biol 2006, 10:362-366.
4. Valentin J.P., Hoffmann P., De Clerck F., Hammond T.G., Hondeghem L. Review of the predictive value of the langendorff heart model (SCREENIT system) in assessing the proarrhythmic potential of drugs. JPharmacol Toxicol Methods 2004, 49:171-181.
5. Recanatini M., Poluzzi E., Masetti M., Cavalli A., De Ponti F. QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005, 25:133-166.
6. Rampe D., Brown A.M. Ahistory of the role of the hERG channel in cardiac risk assessment. JPharmacol Toxicol Methods 2013, 68:13-22.
7. Antzelevitch C. Transmural dispersion of repolarization and the T wave. Cardiovasc Res 2001, 50:426-431.
8. Antzelevitch C. Cardiac repolarization. The long and short of it. Europace 2005, 7:S3-S9.
9. Belardinelli L., Antzelevitch C., Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003, 24:619-625.
10. Liu T.X., Brown B.S., Wu Y., Antzelevitch C., Kowey P.R., Yan G.X. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006, 3:948-956.
11. Hondeghem L.M. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the t-wave, incriminates safe drugs, and misses profibrillatory drugs. JCardiovasc Electrophysiol 2006, 17:337-340.
12. Hondeghem L.M. Relative contributions of TRIaD and QT to proarrhythmia. JCardiovasc Electrophysiol 2007, 18:655-657.
13. Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circ Res 2001, 103:2004-2013.
14. Hondeghem L.M., Lu H.R., Rossem K.V., De Clerck F. Detection of proarrhythmia in the female rabbit heart:. blinded validation. JCardiovasc Electrophysiol 2003, 14:287-294.
15. Lawrence C.L., Bridgland-Taylor M.H., Pollard C.E., Hammond T.G., Valentin J.P. Arabbit langendorff heart proarrhythmia model: predictive value for clinical identification of torsades de pointes. Br J Pharmacol 2006, 149:845-860.
16. Meyer T., Boven K.H., Gunther E., Fejtl M. Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation. Drug Saf 2004, 27:763-772.
17. Natarajan A., Stancescu M., Dhir V., Armstrong C., Sommerhage F., Hickman J.J., et al. Patterned cardiomyocytes on microelectrode arrays as a functional, highinformation content drug screening platform. Biomaterials 2011, 32:4267-4274.
18. Braam S.R., Tertoolen L., van de Stolpe A., Meyer T., Passier R., Mummery C.L. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 2010, 4:107-116.
19. Egert U., Haemmerle H. Application of the microelectrode-array (MEA) technology in pharmaceutical drug research. Sensoren im Fokus neuer Anwendungen 2002, 51-54. w.e.b. Universitätsverlag, Dresden. J.P. Baselt, G. Gerlach (Eds.).
20. 2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. JPharmacol Toxicol Methods 2012, 66:246-256.
21. Park J., Ryu J., Choi S.K., Seo E., Cha J.M., Ryu S., et al. Real-time measurement of the contractile forces of self-organized cardiomyocytes on hybrid biopolymer microcantilevers. Anal Chem 2005, 77:6571-6580.
22. Zhao Y., Zhang X. Cellular mechanics study in cardiac myocytes using PDMS pillars array. Sens Actuat A 2006, 125:398-404.
23. Feinberg A.W., Feigel A., Shevkoplyas S.S., Sheehy S., Whitesides G.M., Parker K.K. Muscular thin films for building actuators and powering devices. Science 2007, 317:1366-1370.
24. Schaaf S., Shibamiya A., Mewe M., Eder A., Stöhr A., Hirt M.N., et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 2011, 6:e26397.
25. Huebsch N., Loskill P., Mandegar M.A., Marks N.C., Sheehan A.S., Ma Z., et al. Automated video-based analysis of contractility and calcium flux in human iPS-derived cardiomyocytes cultured over different spatial scales. Tissue Eng. Part C Methods 2015, 21:1-13.
26. Yin S.H., Zhang X., Zhan C., Wu J., Xu J., Cheung J. Measuring single cardiac myocyte contractile force via moving a magnetic bead. Biophys J 2005, 88:1489-1495.
27. Pillekamp F., Haustein M., Khalil M., Emmelheinz M., Nazzal R., Adelmann R., et al. Contractile properties of early human embryonic stem cell-derived cardiomyocytes: beta-adrenergic stimulation induces positive chronotropy and lusitropy but not inotropy. Stem Cells Dev 2012, 21:2111-2121.
28. Zimmermann W.H., Fink C., Kralisch D., Remmers U., Weil J., Eschenhagen T. Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. Biotechnol Bioeng 2000, 68:106-114.
29. Pampaloni F., Reynaud E.G., Stelzer E.H. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007, 8:839-845.
30. Das M., Wilson K., Molnar P., Hickman J.J. Differentiation of skeletal muscle and integration of myotubes with silicon microstructures using serum-free medium and a synthetic silane substrate. Nat Protoc 2007, 2:1795-1801.
31. Wilson K., Das M., Wahl K.J., Colton R.J., Hickman J.J. Measurement of contractile stress generated by cultured muscle on silicon cantilevers. PLoS One 2010, 5:e11042.
32. Rao C., Prodromakis T., Kolker L., Chaudhry U.A., Trantidou T., Sridhar A., et al. The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials 2013, 34:2399-2411.
33. Das M., Molnar P., Gregory C., Riedel L., Hickman J.J. Long-term culture of embyonic rat cardiomyocytes on an organosilane surface in a serum free medium. Biomaterials 2004, 25:5643-5647.
34. Pointon A., Abi-Gerges N., Cross M.J., Sidaway J.E. Phenotypic profiling of structural cardiotoxins invitro reveals dependency on multiple mechanisms of toxicity. Toxicol Sci 2013, 132:317-326.
35. Popat K.C., Mor G., Grimes C.A., Desai T.A. Surface modification of nanoporous alumina surfaces with poly(ethylene glycol). Langmuir 2004, 20:8035-8041.
36. Reuter H., Seitz N. The dependence of calcium efflux from cardiac muscle on temperature and external ion composition. JPhysiol 1968, 195:451-470.
37. Peng S., Lacerda A.E., Kirsch G.E., Brown A.M., Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. JPharmacol Toxicol Methods 2010, 61:277-286.
38. Nguemo F., Šarić T., Pfannkuche K., Watzele M., Reppel M., Hescheler J. Invitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cell Physiol Biochem 2012, 29:819-832.
39. Harmer A.R., Abi-Gerges N., Morton M.J., Pullen G.F., Valentin J.P., Pollard C.E. Validation of an invitro contractility assay using canine ventricular myocytes. Toxicol Appl Pharmacol 2012, 260:162-172.
40. Wilson K., Molnar P., Hickman J.J. Integration of functional myotubes with a bio-MEMS device for non-invasive interrogation. Lab Chip 2007, 7:920-922.
41. Goldenberg L.I., Boloodwell R.D., Braunwald E., Morrow A.G. The direct effects of norepinephrine, epinephrine, and methoxamine on myocardial contractile force in man. Circulation 1960, 22:1125-1132.
42. Cannom D.S., Rider A.K., Stinson E.B., Harrison D.C. Electrophysiologic studies in the denervated transplanted human heart: II. response to norepinephrine, isoproterenol and propranolol. Am J Cardiol 1975, 36:859-866.
43. Kimura M., Umemura K., Ikeda Y., Kosuge K., Mizuno A., Nakanomyo H., et al. Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers. Br J Clin Pharmacol 1996, 42:583-588.
44. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003, 58:32-45.
45. Mitchell L.B., Wyse D.G., Duff H.J. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987, 76:810-818.
46. Rumsey J.W., Das M., Stancescu M., Bott M., Fernandez-Valle C., Hickman J.J. Node of ranvier formation on motoneurons invitro. Biomaterials 2009, 30:3567-3572.
47. Hondeghem L.M. Computer aided development of antiarrhythmic agents with class IIIa properties. JCardiovasc Electrophysiol 1994, 5:711-721.
48. Guo X., Gonzalez M., Stancescu M., Vandenburgh H., Hickman J.J. Neuromuscular junction formation between human stem cell-derived motoneurons and human skeletal muscle in a defined system. Biomaterials 2011, 32:9602-9611.
49. Varghese K., Molnar P., Das M., Bhargava N., Lambert S., Kindy M.S., et al. Anew target for amyloid beta toxicity validated by standard and high-throughput electrophysiology. PLoS One 2010, 5:e8643.
50. Sung J.H., Esch M.B., Prot J.-M., Long C.J., Smith A., Hickman J.J., et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip 2013, 13:1201-1212.